Cardiff Oncology Inc. (CRDF)
Kurs, die wichtigsten Kennzahlen und die neuesten Nachrichten an einem Ort.
Cardiff Oncology Inc. (CRDF) Aktienkurs, Analyse & Daten
| Geld | 0.63 |
| Marktkapitalisierung | 70.69 Mio |
| Umsatz (TTM) | 508K |
| Nettogewinn (TTM) | -40.08 Mio |
| 1.44 | |
| -0.61 | |
| n/a | |
| -1.55 | |
| KBV (TTM) | 2.35 |
| KUV (TTM) | 139.16 |
| Termin Quartalszahlen | Nov 12, 2026 |
| Brief | 1.17 |
| Volumen | 554,191 |
| Ø Vol. (20D) | 1,480,667 |
| Eröffnung | 0.90 |
| Vortagesschluss | 0.90 |
| Tagesspanne | 0.87 - 0.92 |
| 52-Wk Range | 0.76 - 3.31 |
| Analyst | n/a |
| Kursziel | n/a |
| Dividenden | n/a |
| Ex-Dividenden-Datum | n/a |
Über CRDF
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small...
Finanzielle Entwicklung
Im Jahr 2025 betrug der Umsatz von Cardiff Oncology 593K, ein Rückgang von -13.18% im Vergleich zum Vorjahr (683K). Der Gewinn lag bei -45.85 Mio, ein Anstieg von 0.92 %.
FinanzberichteGewinnüberraschung
Analysten erwarten einen Umsatz von ... Upgrade
vor 3 Monaten · Simply Wall St.
Cardiff Oncology And 2 Other Promising Penny Stocks For Your WatchlistOver the last 7 days, the U.S. market has dropped by 1.0%, yet it has risen by 23% over the past year, with earnings forecasted to grow annually by 17%. In such a fluctuating market, identifying stock...
